WO2003086465A1 - Drugs for myopia correction surgery - Google Patents

Drugs for myopia correction surgery Download PDF

Info

Publication number
WO2003086465A1
WO2003086465A1 PCT/JP2003/004557 JP0304557W WO03086465A1 WO 2003086465 A1 WO2003086465 A1 WO 2003086465A1 JP 0304557 W JP0304557 W JP 0304557W WO 03086465 A1 WO03086465 A1 WO 03086465A1
Authority
WO
WIPO (PCT)
Prior art keywords
surgery
correction
medicament
intraocular pressure
active ingredient
Prior art date
Application number
PCT/JP2003/004557
Other languages
French (fr)
Japanese (ja)
Inventor
Tomiya Mano
Mayumi Mano
Shunji Sogo
Original Assignee
Mei Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Co., Ltd. filed Critical Mei Co., Ltd.
Priority to AU2003236044A priority Critical patent/AU2003236044A1/en
Publication of WO2003086465A1 publication Critical patent/WO2003086465A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a medicament for myopic correction surgery. More specifically, the present invention relates to a medicament capable of improving the treatment results of myopic correction surgery. Background art
  • myopia correction surgery In recent years, surgery to change the refractive index of the cornea by shaving and flattening the cornea using a laser has been adopted as a radical treatment for myopia (hereinafter, this surgery is referred to as “myopia correction surgery” in this specification). Or “LASIK”). This operation involves shaving the corneal surface using a microkeratome, creating and turning up the corneal flap, then shaving the exposed corneal stroma by laser irradiation, and returning the corneal flap to its original state.
  • An object of the present invention is to provide a medicine capable of increasing the success rate of myopic correction surgery.
  • the present inventors conducted intensive research to solve the above-mentioned problems, and as a result, after temporary visual acuity recovery was observed in myopic correction surgery, patients with recurrent myopia and low correction tendency were recognized. It has been found that good topical recovery and stabilization can be achieved by topically administering a drug having an intraocular pressure-lowering effect to a patient.
  • the present invention is based on the above findings. It was completed.
  • the present invention provides a medicament for increasing the success rate of myopic correction surgery, which contains a substance having an intraocular pressure lowering effect as an active ingredient.
  • the medicament of the present invention can be locally administered, for example, into the eye after surgery to increase the success rate of myopic surgery. More preferably, when the desired visual acuity recovery cannot be achieved after myopic correction surgery, when myopia reappears after temporary visual acuity recovery is observed, or when low correction tendency is observed after surgery or when visual acuity recovery is stable It can be used when conversion is not enough.
  • a medicament for preventing re-myopia occurring after surgery for myopic correction surgery which comprises a substance having an intraocular pressure lowering effect as an active ingredient, and a medicament for post-operative surgery for myopia correction surgery
  • a drug for stabilizing visual acuity recovery of a subject comprising a substance having an intraocular pressure-lowering action as an active ingredient, and a drug for improving a post-operative low correction tendency in myopic correction surgery, comprising:
  • a medicament comprising a substance having a pressure-lowering effect as an active ingredient is provided.
  • the above-mentioned composition containing one or two or more substances selected from the group consisting of a prostaglandin F2a preparation, a J3 block strength preparation, and a carbonic anhydrase inhibitor as an active ingredient pharmaceutical; above, including the quality ones the intraocular pressure reducing achievable as an active ingredient to normal intraocular pressure pharmaceutical; from the group consisting of prostaglandin F 2 alpha formulations ⁇ Pi blanking opening Kka formulation 1 or 2 or more selected.
  • a method for increasing the success rate of myopic correction surgery which comprises a step of administering an effective amount of a substance having an intraocular pressure-lowering effect to a patient, preferably a step of topically administering the substance to a post-operative eye.
  • Method a method for preventing re-myopia that occurs after surgery for myopic correction surgery, comprising administering to a patient a prophylactically effective amount of a substance having an intraocular pressure-lowering effect, preferably, topically administering to the eye after surgery.
  • a method for stabilizing post-operative visual acuity recovery after myopia correction surgery comprising administering to a patient an effective amount of a substance having an intraocular pressure-lowering effect, preferably in the post-operative eye.
  • a method is provided that includes the step of topical administration.
  • the active ingredient of the medicament of the present invention is not particularly limited as long as it is a substance having an intraocular pressure effect.
  • an intraocular pressure reducing agent used for treating glaucoma can be used. More specifically, prostaglandin F 2 a formulation (isopropyl Uno Prostone, etc. latanoprost), blocker formulation (timolol maleate, hydrochloric base Funororu, carteolol hydrochloride, such as hydrochloric base Takisororu), alpha Purokka one (bunazosin hydrochloride, etc.
  • a J3 blocker Naprazol
  • carbonic anhydrase inhibitors acetazolamide, dichlorphenamide, methazolamide, etc.
  • acetazolamide, dichlorphenamide, methazolamide, etc. are used for the treatment of glaucoma.
  • These medicaments can be used as they are as the medicament of the present invention.
  • the medicament of the present invention may contain two or more of these substances having an intraocular pressure-lowering effect.
  • two or more pharmaceutical agents of the present invention containing different active ingredients can be administered.
  • a substance that can further reduce intraocular pressure with respect to normal intraocular pressure can be used.
  • antiglaucoma agent having such properties pro static Grande in F 2 alpha formulations or] 3 block force one formulation are known, these can be used as the preferred active ingredient of the present onset Ming pharmaceutical.
  • the medicament of the present invention is usually administered topically to the eye, and can preferably be administered as eye drops, but a dosage form by parenteral administration such as oral administration or injection can also be selected.
  • the form of topical administration into the eye is not particularly limited, and a pharmaceutical such as an ophthalmic ointment in addition to an aqueous eye drop can be used.
  • the medicament of the present invention can be used to enhance the therapeutic results of myopic surgery. More specifically, it can be administered for the purpose of visual acuity recovery to a patient who does not recover to a desired corrected visual acuity after myopic correction surgery. It can also be used to restore visual acuity and prevent the progression of myopia in patients who have a tendency to re-myopia after visual acuity has been restored by myopic correction surgery. Further, the medicament of the present invention can be administered prophylactically so as to stabilize the visual acuity recovered by myopic correction surgery and prevent re-myopia from progressing. Without being bound by any particular theory, the mechanism of action of the medicament of the present invention is believed to be as follows.
  • the postoperative course was favorable.
  • the medicament of the present invention can improve the treatment results of myopic surgery, and is useful for preventing post-operative myopia re-evaluation and improving the tendency of low myopia.

Abstract

Drugs for preventing recurrence of myopia after a myopia correction surgery (LASIK), stabilizing recovery in eyesight after a myopia correction surgery and/or improving postoperative depression in the correction effect to thereby elevate the success rate of the myopia correction surgery, which contain as the active ingredient a substance having an effect of lowering ocular tension such as a prostaglandin F2α preparation.

Description

明 細 書 近視矯正手術のための医薬 技術分野  Description Medical technology for myopic surgery
本発明は近視矯正手術のための医薬に関する。 より具体的には、 本発明は、 近 視矯正手術の治療成績を高めることができる医薬に関するものである。 背景技術  The present invention relates to a medicament for myopic correction surgery. More specifically, the present invention relates to a medicament capable of improving the treatment results of myopic correction surgery. Background art
近年、 近視の根治的治療法として、 レーザーを用いて角膜を削り扁平化させる ことによって角膜の屈折率を変化させる手術が採用されている （以下、 本明細書 においてこの手術を「近視矯正手術」又は「L A S I K」 と呼ぶ。）。 この手術は、 マイクロケラトームを用いて角膜表層を削り、 角膜フラップを作成してめくり上 げた後、 露出した角膜実質をレーザー照射により削り、 角膜フラップを元にもど す操作を含んでいる。この手術を行うにあたり、術前に視力の詳細な検査を行レヽ、 術後に得ようとする目標視力に合わせて角膜実質を削る程度を決定する必要があ るが、 手術後にはほとんどの症例において目標視力を得ることができ、 しかもそ の視力は安定していることから、この手術の適用が拡大している。しかしながら、 一部の症例では、 一時的な視力回復が認められた後、 再び近視化を生じる場合や 所望の視力回復が得られなレ、場合があつた。 発明の開示  In recent years, surgery to change the refractive index of the cornea by shaving and flattening the cornea using a laser has been adopted as a radical treatment for myopia (hereinafter, this surgery is referred to as “myopia correction surgery” in this specification). Or "LASIK"). This operation involves shaving the corneal surface using a microkeratome, creating and turning up the corneal flap, then shaving the exposed corneal stroma by laser irradiation, and returning the corneal flap to its original state. In performing this operation, it is necessary to perform a detailed inspection of the visual acuity before the operation and determine the degree of shaving the corneal stroma in accordance with the target visual acuity to be obtained after the operation, but in most cases after the operation Since the target vision can be obtained at, and the vision is stable, the application of this surgery is expanding. However, in some cases, after temporary visual acuity recovery was observed, myopia may reappear, or the desired visual acuity recovery may not be achieved. Disclosure of the invention
本発明の課題は、 近視矯正手術の成功率を高めることができる医薬を提供する ことにある。 本発明者らは上記の課題を解決すべく鋭意研究を行った結果、 近視 矯正手術において一時的な視力回復が認められた後、再ぴ近視化を生じた患者や、 低矯正傾向を認めた患者に眼圧降下作用を有する医薬を局所投与することにより、 良好な視力回復と安定化を達成できることを見出した。 本発明は上記の知見を基 にして完成されたものである。 An object of the present invention is to provide a medicine capable of increasing the success rate of myopic correction surgery. The present inventors conducted intensive research to solve the above-mentioned problems, and as a result, after temporary visual acuity recovery was observed in myopic correction surgery, patients with recurrent myopia and low correction tendency were recognized. It has been found that good topical recovery and stabilization can be achieved by topically administering a drug having an intraocular pressure-lowering effect to a patient. The present invention is based on the above findings. It was completed.
すなわち、 本発明は、 近視矯正手術の成功率を高めるための医薬であって、 眼 圧降下作用を有する物質を有効成分として含む医薬を提供するものである。 本発 明の医薬は、 近視矯正手術の成功率を高める目的で、 例えば手術後の眼内に局所 投与することができる。 より好ましくは、 近視矯正手術後に所望の視力回復が達 成できない場合、 一時的な視力回復が認められた後に再び近視化を生じる場合、 あるいは術後に低矯正傾向を認める場合や視力回復の安定化が十分ではない場合 に用いることができる。 また、 本発明により、 近視矯正手術の術後に生じる再近 視化を予防するための医薬であって、 眼圧降下作用を有する物質を有効成分とし て含む医薬、 及び近視矯正手術の術後の視力回復を安定化させるための医薬であ つて、 眼圧降下作用を有する物質を有効成分として含む医薬、 及び近視矯正手術 の術後の低矯正傾向を改善するための医薬であって、 眼圧降下作用を有する物質 を有効成分として含む医薬が提供される。  That is, the present invention provides a medicament for increasing the success rate of myopic correction surgery, which contains a substance having an intraocular pressure lowering effect as an active ingredient. The medicament of the present invention can be locally administered, for example, into the eye after surgery to increase the success rate of myopic surgery. More preferably, when the desired visual acuity recovery cannot be achieved after myopic correction surgery, when myopia reappears after temporary visual acuity recovery is observed, or when low correction tendency is observed after surgery or when visual acuity recovery is stable It can be used when conversion is not enough. Further, according to the present invention, a medicament for preventing re-myopia occurring after surgery for myopic correction surgery, which comprises a substance having an intraocular pressure lowering effect as an active ingredient, and a medicament for post-operative surgery for myopia correction surgery A drug for stabilizing visual acuity recovery of a subject, comprising a substance having an intraocular pressure-lowering action as an active ingredient, and a drug for improving a post-operative low correction tendency in myopic correction surgery, comprising: A medicament comprising a substance having a pressure-lowering effect as an active ingredient is provided.
本発明の好ましい態様によれば、 プロスタグランディン F 2 a製剤、 J3ブロッ力 一製剤、 及ぴ炭酸脱水素酵素阻害剤からなる群から選ばれる 1又は 2以上の物質 を有効成分として含む上記の医薬；正常な眼圧に対して眼圧降下を達成できる物 質を有効成分として含む上記の医薬；プロスタグランディン F 2 α製剤及ぴ ブ口 ッカー製剤からなる群から選ばれる 1又は 2以上の物質を有効成分として含む上 記の医薬が提供される。 According to a preferred embodiment of the present invention, the above-mentioned composition containing one or two or more substances selected from the group consisting of a prostaglandin F2a preparation, a J3 block strength preparation, and a carbonic anhydrase inhibitor as an active ingredient pharmaceutical; above, including the quality ones the intraocular pressure reducing achievable as an active ingredient to normal intraocular pressure pharmaceutical; from the group consisting of prostaglandin F 2 alpha formulations及Pi blanking opening Kka formulation 1 or 2 or more selected The above-mentioned medicine containing a substance as an active ingredient is provided.
また、 本発明により、 近視矯正手術の成功率を高める方法であって、 眼圧降下 作用を有する物質の有効量を患者に投与する工程、 好ましくは術後の眼内に局所 投与する工程を含む方法；近視矯正手術の術後に生じる再近視化の予防方法であ つて、 眼圧降下作用を有する物質の予防有効量を患者に投与する工程、 好ましく は術後の眼内に局所投与する工程を含む方法；及ぴ近視矯正手術の術後の視力回 復を安定化する方法であって、 眼圧降下作用を有する物質の有効量を患者に投与 する工程、 好ましくは術後の眼内に局所投与する工程を含む方法が提供される。 発明を実施するための最良の形態 Further, according to the present invention, there is provided a method for increasing the success rate of myopic correction surgery, which comprises a step of administering an effective amount of a substance having an intraocular pressure-lowering effect to a patient, preferably a step of topically administering the substance to a post-operative eye. Method: a method for preventing re-myopia that occurs after surgery for myopic correction surgery, comprising administering to a patient a prophylactically effective amount of a substance having an intraocular pressure-lowering effect, preferably, topically administering to the eye after surgery. And a method for stabilizing post-operative visual acuity recovery after myopia correction surgery, comprising administering to a patient an effective amount of a substance having an intraocular pressure-lowering effect, preferably in the post-operative eye. A method is provided that includes the step of topical administration. BEST MODE FOR CARRYING OUT THE INVENTION
本発明の医薬の有効成分としては、 眼圧効果作用を有する物質であれば特に限 定されないが、 例えば、 緑内障の治療に用いられている眼圧降下剤を用いること ができる。 より具体的には、 プロスタグランディン F 2 a製剤 （イソプロピルウノ プロストン、 ラタノプロストなど）、 ブロッカー製剤 （マレイン酸チモロール、 塩酸べフノロール、塩酸カルテオロール、塩酸べタキソロールなど）、 αプロッカ 一 （塩酸ブナゾシンなど）、 a J3ブロッカー （二プラジ口ール）、 及び炭酸脱水素 酵素阻害剤 （ァセタゾラミ ド、 ジクロルフエナミド、 メタゾラミ ドなど） などの 眼圧降下剤が緑内障の治療に用いられているので、 本発明の医薬としてこれらの 医薬をそのまま用いることが可能である。 本発明の医薬としては、 眼圧降下作用 を有するこれらの物質を 2種以上含むものであってもよい。 また、 異なる有効成 分を含む本発明の医薬の 2種以上を投与することもできる。 The active ingredient of the medicament of the present invention is not particularly limited as long as it is a substance having an intraocular pressure effect. For example, an intraocular pressure reducing agent used for treating glaucoma can be used. More specifically, prostaglandin F 2 a formulation (isopropyl Uno Prostone, etc. latanoprost), blocker formulation (timolol maleate, hydrochloric base Funororu, carteolol hydrochloride, such as hydrochloric base Takisororu), alpha Purokka one (bunazosin hydrochloride, etc. ), A J3 blocker (Niprazol) and carbonic anhydrase inhibitors (acetazolamide, dichlorphenamide, methazolamide, etc.) are used for the treatment of glaucoma. These medicaments can be used as they are as the medicament of the present invention. The medicament of the present invention may contain two or more of these substances having an intraocular pressure-lowering effect. In addition, two or more pharmaceutical agents of the present invention containing different active ingredients can be administered.
好ましい有効成分としては、 正常な眼圧に対してもさらに眼圧降下を達成でき る物質を用いることができる。 このような性質を有する眼圧降下剤として、 プロ スタグランデイン F 2 α製剤又は ]3ブロッ力一製剤が知られており、 これらを本発 明の医薬の好ましい有効成分として用いることができる。 本発明の医薬は通常は 眼内に局所投与され、 好ましくは点眼剤として投与することができが、 経口投与 や注射などの非経口投与による投与形態も選択できる。 眼内への局所投与の形態 は特に限定されず、 水性の点眼剤のほか、 眼軟膏剤などの形態の医薬であっても さしっかえない。 As a preferable active ingredient, a substance that can further reduce intraocular pressure with respect to normal intraocular pressure can be used. As antiglaucoma agent having such properties, pro static Grande in F 2 alpha formulations or] 3 block force one formulation are known, these can be used as the preferred active ingredient of the present onset Ming pharmaceutical. The medicament of the present invention is usually administered topically to the eye, and can preferably be administered as eye drops, but a dosage form by parenteral administration such as oral administration or injection can also be selected. The form of topical administration into the eye is not particularly limited, and a pharmaceutical such as an ophthalmic ointment in addition to an aqueous eye drop can be used.
本発明の医薬は、近視矯正手術の治療成績を高めるために用いることができる。 より具体的には、近視矯正手術後に所望の矯正視力まで回復しない患者に対して、 視力回復を目的として投与することができる。 また、 近視矯正手術によりいった ん視力が回復した後、 再近視化傾向を認める患者に対して視力回復及び近視の進 行予防のために用いることができる。 さらに、 近視矯正手術により回復した視力 を安定化させ、 再近視化が進行しないように予防的に本発明の医薬を投与するこ ともできる。 いかなる特定の理論に拘泥するわけではないが、 本発明の医薬の作用機序は以 下のように考えられる。 近視矯正手術において角膜フラップの作製おょぴレーザ 一による菲薄化により、 創傷治癒が完了 （特に角膜フラップの接着） するまで角 膜は正常な強度を持たず、 眼圧により曲率が増した状況下に置かれている。 この 状態で創傷治癒が完了すると矯正手術により得ようとした角膜の扁平化が不足す ることになり、 目標視力が得られないことになるが、 このような状態において眼 圧を降下させることにより、 角膜強度が回復までの期間にわたり角膜曲率の増加 を抑制することができ、 目標とする角膜扁平率を得ることができる。 The medicament of the present invention can be used to enhance the therapeutic results of myopic surgery. More specifically, it can be administered for the purpose of visual acuity recovery to a patient who does not recover to a desired corrected visual acuity after myopic correction surgery. It can also be used to restore visual acuity and prevent the progression of myopia in patients who have a tendency to re-myopia after visual acuity has been restored by myopic correction surgery. Further, the medicament of the present invention can be administered prophylactically so as to stabilize the visual acuity recovered by myopic correction surgery and prevent re-myopia from progressing. Without being bound by any particular theory, the mechanism of action of the medicament of the present invention is believed to be as follows. Preparation of corneal flaps in myopic correction surgery With laser thinning, the cornea does not have normal strength until wound healing is completed (especially adhesion of corneal flaps) and curvature increases due to intraocular pressure Has been placed. If the wound healing is completed in this state, the cornea flattened by corrective surgery will be insufficient, and the target visual acuity will not be obtained. However, it is possible to suppress an increase in corneal curvature over a period until the corneal strength recovers, and to obtain a target corneal flattening ratio.
本発明の医薬の投与量は有効成分の種類や作用の程度により適宜選択すること ができるが、 一般的には、 緑内障の治療の目的で眼圧降下させる場合の投与量を めやすとして同程度の投与量を選択することができる。 本発明の医薬の投与時期 及び投与期間も特に限定されず、 適宜選択することが可能である。 例えば、 近視 矯正手術の直後に投与することもできるが、 一般的には近視矯正手術後の視力回 復を数日から数週間観察した後、 低矯正傾向が認められる場合に本発明の医薬を 数週間から数ケ月間投与することが望ましい。本発明の医薬は、近視矯正手術後、 数ケ月ないし数年後に投与しても有効な場合がある。本発明の医薬の投与回数は、 有効成分の種類や達成すべき眼圧降下の程度などにより適宜選択可能であるが、 緑内障治療のために眼圧降下させる場合をめやすに、 一日あたり 1ないし数回投 与することができる。 実施例 .  The dose of the medicament of the present invention can be appropriately selected depending on the kind of the active ingredient and the degree of action, but generally, the same dose as that for reducing intraocular pressure for the purpose of treating glaucoma is used. The dose can be chosen. The administration time and administration period of the medicament of the present invention are not particularly limited, and can be appropriately selected. For example, the medicament of the present invention can be administered immediately after myopic correction surgery. It is desirable to administer for weeks to months. The medicament of the present invention may be effective even if administered several months to several years after myopic surgery. The number of administrations of the medicament of the present invention can be appropriately selected depending on the type of the active ingredient, the degree of intraocular pressure reduction to be achieved, and the like. Can be given several times. Example .
以下、 本発明を実施例によりさらに具体的に説明するが、 本発明の範囲は下記 の実施例に限定されることはない。 実施例中、 本発明の医薬としてラタノブラス ト（Latanoprost、 プロスタグランジン誘導体、 製品名 「キサラタン」 （Xalatan)、 0. 005%, 製造元/販売元：フアルマシア ·アップジョン）、 及びマレイン酸チモロ ール（Timolol maleate、 j3ブロッカー、製品名「チモプトール」（Timoptol)、 0. 5%、 製造元：萬有製薬株式会社、 販売元：参天製薬株式会社） を用いた。 実施例 1 Hereinafter, the present invention will be described more specifically with reference to Examples, but the scope of the present invention is not limited to the following Examples. In the examples, as the medicament of the present invention, latanoblast (Latanoprost, a prostaglandin derivative, product name “Xalatan”, 0.005%, manufacturer / distributor: Pharmacia Upjohn), and timolol maleate (Timolol maleate, j3 blocker, product name “Timoptol” (Timoptol), 0.5%, manufacturer: Banyu Pharmaceutical Co., Ltd., sales agency: Santen Pharmaceutical Co., Ltd.) Example 1
33歳女性。 現病歴：平成 12年 9月 4日、 両眼の視力矯正手術 （LASIK) 目的に 初診時検查結果：  33 year old female. Current medical history: September 4, 2000, for the purpose of binocular vision correction surgery (LASIK)
視力 右眼 裸眼 =0.04、 矯正 =(1.0XS— 8.75D： C-2.0D A 5。 ) Visual acuity right eye naked eye = 0.04, correction = (1.0XS—8.75D: C-2.0D A5.)
左眼 裸眼 =0.04、 矯正 =(0.9XS— 10.25D： C— 3.0D A 175° ) 眼圧 右眼 =15腿 、 左眼- l½mHg  Left eye naked eye = 0.04, correction = (0.9XS-10.25D: C-3.0D A 175 °) intraocular pressure right eye = 15 thighs, left eye-l½mHg
平成 12年 11月 1日 両眼に LASIKを行つた。 November 1, 2000 LASIK was performed on both eyes.
術後視力は良好で術後 1ヶ月の視力は Postoperative visual acuity is good.
右眼裸眼 =0.8、 右眼矯正 = (1. O S+0.75D： C一 1.25D A 30。 ) Right eye naked eye = 0.8, right eye correction = (1. OS + 0.75D: C-1.25D A30.)
左眼裸眼 =0.9、 左眼矯正=(1.0 3+0.751) : (—1.251) 165° ) Left naked eye = 0.9, Left eye correction = (1.0 3 + 0.751): (--1.251) 165 °)
であり、 術後経過は順調であった。 The postoperative course was favorable.
しかし、平成 14年 2月 1日（術後約 1年 3力月）に両眼の視力低下を自覚し来院し た。 However, she visited the hospital on February 1, 2002 (about 1 year and 3 months after the operation), conscious of decreased vision in both eyes.
右眼裸眼 =0.6、 矯正- (1.0XS-0.5D： C-0.75D A 30° ) Right eye naked = 0.6, correction-(1.0XS-0.5D: C-0.75D A 30 °)
左眼裸眼 =0.4、 矯正 =(1.0 p XS-0.75D： C-1.25D A 150° ) Left eye naked eye = 0.4, correction = (1.0 p XS-0.75D: C-1.25D A 150 °)
となっていた。そこでラタノプロスト点眼を両眼に 1日 1回、 0.5%マレイン酸チ モロール点眼を両眼に 1日 2回を開始した。 It was. Therefore, latanoprost instillation was started in both eyes once a day, and 0.5% timolol maleate was started in both eyes twice a day.
その結果、 平成 14年 3月 5日（点眼開始後 1ヶ月）には As a result, on March 5, 2002 (one month after the start of instillation)
右眼裸眼 =1.0、 矯正 = (1. OxS+0.25D :C-0.50D Αχ10° ) Right naked eye = 1.0, Correction = (1.OxS + 0.25D: C-0.50D Αχ10 °)
左眼裸眼 =0.8、 矯正 = (1. OxS+0.50D ： C-1.25D Axl60° ) Left naked eye = 0.8, Correction = (1. OxS + 0.50D: C-1.25D Axl60 °)
眼圧 右眼 = 14mmHg、 左眼- 13固 Hg Intraocular pressure Right eye = 14mmHg, Left eye-13 solid Hg
となり裸眼視力の改善を認、めた。 実施例 2 The improvement of naked eye vision was observed. Example 2
37歳女性。 現病歴：平成 13年 5月 29日、 両眼の LASIK目的に受診。 初診時検査結果： 37 years old woman. Current medical history: On May 29, 2001, she was consulted for LASIK purposes for both eyes. Test results at first consultation:
視力 右眼 裸眼 =0.01、 矯正 =(L0XS— 11.5D： C— 2.25D A 10° ) Visual acuity right eye naked eye = 0.01, correction = (L0XS—11.5D: C—2.25D A 10 °)
左眼 裸眼 =0.02、 矯正 =(1.0XS— 8.5D： C— 2.0D A 170° )  Left eye naked eye = 0.02, correction = (1.0XS-8.5D: C-2.0D A 170 °)
眼圧 右眼 = 13mmHg、 左眼 -llmmHg IOP Right eye = 13mmHg, Left eye -llmmHg
平成 13年 6月 21日 両眼に LASIKを行つた。 June 21, 2001 LASIK was performed on both eyes.
術後より低矯正傾向であり平成 14年 1月 8日（術後 6ヶ月半）には The level of correction was lower than postoperatively. On January 8, 2002 (6 and a half months after operation)
右眼裸眼 =0.2、 右眼矯正 =(1.0xS- 2.0D :C-0.5D Axl40° ) Right eye naked eye = 0.2, right eye correction = (1.0xS- 2.0D: C-0.5D Axl40 °)
左眼裸眼 =0.3、 左眼矯正 =(1.0XS+0.75D： C一 1.25D A 165° ) Left eye naked eye = 0.3, Left eye correction = (1.0XS + 0.75D: C-1.25D A 165 °)
となった。 そこで裸眼視力改善の目的でラタノブロスト点眼を両眼に 1日 1回、 0.5%マレイン酸チモロール点眼を両眼に 1日 2回を開始した。 It became. Therefore, for the purpose of improving the visual acuity of the naked eye, latanoblost instillation was started once a day in both eyes, and 0.5% timolol maleate was started twice a day in both eyes.
その結果、 平成 14年 2月 19日（点眼開始後 1力月半）には As a result, on February 19, 2002 (one and a half months after the start of instillation)
右眼裸眼 =1.0、 矯正 =(1.2xS+0.5D ： C-0.25D Axl30° ) Right eye naked = 1.0, Correction = (1.2xS + 0.5D: C-0.25D Axl30 °)
左眼裸眼 =1.0、 矯正 = (1. OxS+0.75D ： C-l.5D Ax 100° ) Left eye naked eye = 1.0, correction = (1. OxS + 0.75D: C-l.5D Ax 100 °)
眼圧 右眼 =7mmHg、 左眼 =9mmHg IOP Right eye = 7mmHg, Left eye = 9mmHg
となり裸眼視力に改善を認めた。 実施例 3 And improved eyesight was observed. Example 3
50歳女性。 現病歴：平成 13年 8月 21日、 左眼の LASIK目的に受診。  50 year old woman. Current medical history: On August 21, 2001, she was consulted for LASIK for the left eye.
初診時検查結果： Initial examination results:
視力 左眼 裸眼 =0.06、 矯正 =(1.0XS— 7.5D： C— 1.75D A 90° ) Eyesight Left eye Naked eye = 0.06, Correction = (1.0XS—7.5D: C—1.75D A 90 °)
眼圧 左眼 = 13mmHg IOP Left eye = 13mmHg
平成 13年 10月 18日 左眼に LASIK施行 October 18, 2001 LASIK for left eye
術後 1ヶ月の裸眼視力は 0.6と良好であつたが、 平成 13年 12月 25日（術後約 2 力月）に One month after the operation, the naked-eye visual acuity was good at 0.6, but on December 25, 2001 (about two months after the operation).
左眼裸眼 =0.15、 矯正=(1.0 3— 2.50 : (：—1.250 A 10。 ) Left naked eye = 0.15, correction = (1.0 3-2.50: (:-1.250 A 10.)
と裸眼視力に低下を認めた。そこでラタノプロスト点眼を左眼に 1日 1回、 0.5% マレイン酸チモロール点眼を左眼に 1日 2回を開始した。 その結果、 平成 14年 1月 29日（点眼開始後 1ヶ月）には And a decrease in visual acuity with the naked eye was observed. Therefore, latanoprost instillation was started once daily for the left eye and 0.5% timolol maleate was started twice daily for the left eye. As a result, on January 29, 2002 (one month after the start of instillation)
左眼裸眼 =0.5、 矯正 = (1. OxS-1.25D Ax65° ) Left eye naked eye = 0.5, correction = (1.OxS-1.25D Ax65 °)
眼圧 左眼 =7mmHg IOP Left eye = 7mmHg
となり裸眼視力の改善を認めた。 実施例 4 The improvement of naked eye vision was recognized. Example 4
47歳男性。 現病歴：平成 13年 8月 28日、 左眼の LASIK目的に受診。  47 year old man. Current medical history: On August 28, 2001, she was consulted for LASIK for the left eye.
初診時検査結果： Test results at first consultation:
視力 左眼 裸眼 =0.06、 矯正 =(1.0XS— 2.0D： C— 1.0D Ax85° ) Eyesight Left eye Naked eye = 0.06, Correction = (1.0XS—2.0D: C—1.0D Ax85 °)
眼圧 左眼 = 16mmHg IOP Left eye = 16mmHg
平成 13年 9月 6日 左眼に LASIKを行つた。 September 6, 2001 LASIK was performed on the left eye.
術後 1ヶ月の裸眼視力は 1.2と良好であつたが、 平成 13年 12月 25日（術後約 3 力月）には One-month postoperative visual acuity was good at 1.2, but on December 25, 2001 (about three months after the operation),
左眼裸眼 =0.5p、 矯正 =(1.2p XS— 0.5D： C— 0.25D A 170° ) Left naked eye = 0.5p, correction = (1.2p XS-0.5D: C-0.25D A 170 °)
と裸眼視力に低下を認めた。経過観察を行い平成 14年 1月 29日（術後約 4力月半） には And a decrease in visual acuity with the naked eye was observed. Follow-up was conducted and on January 29, 2002 (approximately four and a half months after the operation)
左眼裸眼 =0.9p、 矯正 =(1·0ρ XS—0.25D： C— 0.25D Ax 140。 ） Left naked eye = 0.9p, Correction = (1.0p XS-0.25D: C-0.25D Ax 140.)
となつたが裸眼視力に日内変動があるという自覚があった。 そこでラタノブロス ト点眼を左眼に 1日 1回開始した。 But I realized that there was a diurnal variation in my naked eyesight. Therefore, he started using rattancrost once a day with his left eye.
その結果、 平成 14年 3月 19日（点眼開始後 1力月半）には As a result, on March 19, 2002 (one and a half months after the start of instillation)
左眼裸眼 =1.0、 矯正 = (1. OxC- 0.5D Ax5° ) Left naked eye = 1.0, correction = (1. OxC- 0.5D Ax5 °)
眼圧 左眼 =15mmHg IOP Left eye = 15mmHg
となり裸眼視力の改善を認めた。 産業上の利用可能性 The improvement of naked eye vision was recognized. Industrial applicability
本発明の医薬は、 近視矯正手術の治療成績を高めることができ、 手術後の再近 視化の予防や低矯正傾向の改善などに有用である。  The medicament of the present invention can improve the treatment results of myopic surgery, and is useful for preventing post-operative myopia re-evaluation and improving the tendency of low myopia.

Claims

請求 の 範 囲 The scope of the claims
1 . 近視矯正手術の成功率を高めるための医薬であって、 眼圧降下作用を有する 物質を有効成分として含む医薬。 1. A medicament for increasing the success rate of myopic correction surgery, which contains a substance having an intraocular pressure lowering effect as an active ingredient.
2 . 近視矯正手術の術後に生じる再近視化を予防するための医薬であって、 眼圧 降下作用を有する物質を有効成分として含む医薬。  2. A medicament for preventing re-myopia that occurs after surgery for myopic correction surgery, which contains as an active ingredient a substance having an intraocular pressure lowering effect.
3 . 近視矯正手術の術後の視力回復を安定化させるための医薬であって、 眼圧降 下作用を有する物質を有効成分として含む医薬。  3. A medicament for stabilizing postoperative visual acuity recovery after myopic surgery, which contains a substance having an intraocular pressure lowering effect as an active ingredient.
4 . 近視矯正手術の術後の低矯正傾向を改善するための医薬であって、 眼圧降下 作用を有する物質を有効成分として含む医薬。  4. A medicament for improving postoperative low correction tendency of myopic correction surgery, which contains a substance having an intraocular pressure lowering effect as an active ingredient.
5 . プロスタグランディン F 2 a製剤、 ブロッカー製剤、 及び炭酸脱水素酵素阻 害剤からなる群から選ばれる 1又は 2以上の物質を有効成分として含む請求の範 囲第 1項ないし第 4項のいずれか 1項に記載の医薬。 5. The method according to any one of claims 1 to 4, wherein the active ingredient comprises one or more substances selected from the group consisting of a prostaglandin F2a preparation, a blocker preparation, and a carbonic anhydrase inhibitor. The medicament according to any one of the preceding claims.
6 . 正常な眼圧に対して眼圧降下を達成できる物質を有効成分として含む請求の 範囲第 1項ないし第 4項のいずれか 1項に記載の医薬。  6. The medicament according to any one of claims 1 to 4, comprising, as an active ingredient, a substance capable of achieving a reduction in intraocular pressure with respect to normal intraocular pressure.
PCT/JP2003/004557 2002-04-12 2003-04-10 Drugs for myopia correction surgery WO2003086465A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003236044A AU2003236044A1 (en) 2002-04-12 2003-04-10 Drugs for myopia correction surgery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002109992A JP2005289814A (en) 2002-04-12 2002-04-12 Medicine for myopia correction surgery
JP2002-109992 2002-04-12

Publications (1)

Publication Number Publication Date
WO2003086465A1 true WO2003086465A1 (en) 2003-10-23

Family

ID=29243216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/004557 WO2003086465A1 (en) 2002-04-12 2003-04-10 Drugs for myopia correction surgery

Country Status (3)

Country Link
JP (1) JP2005289814A (en)
AU (1) AU2003236044A1 (en)
WO (1) WO2003086465A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105998030A (en) * 2016-05-17 2016-10-12 温州医科大学 Application of prostaglandin F2a receptor stimulant in preparation of drug for inhibiting myopia and application method of prostaglandin F2a receptor stimulant
WO2022136192A1 (en) * 2020-12-23 2022-06-30 Essilor International Method of evaluating the efficiency of a myopia control solution

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021145355A1 (en) * 2020-01-15 2021-07-22 参天製薬株式会社 Pharmaceutical composition for treating myopia, preventing myopia, and/or suppressing progression of myopia
WO2021145356A1 (en) * 2020-01-15 2021-07-22 参天製薬株式会社 Drug composition for treating nearsightedness, preventing nearsightedness, and/or minimizing progression of nearsightedness

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086061A (en) * 1988-02-25 1992-02-04 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Use of beta blockers for the treatment of the progression of infantile axial myopia
WO1996029079A1 (en) * 1995-03-20 1996-09-26 Katsuhiko Mukai Ophthalmological composition comprising activated vitamin d
WO2000044383A1 (en) * 1999-01-29 2000-08-03 Senju Pharmaceutical Co., Ltd. Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives
WO2001034554A1 (en) * 1999-11-09 2001-05-17 Alcon Universal Ltd. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086061A (en) * 1988-02-25 1992-02-04 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Use of beta blockers for the treatment of the progression of infantile axial myopia
WO1996029079A1 (en) * 1995-03-20 1996-09-26 Katsuhiko Mukai Ophthalmological composition comprising activated vitamin d
WO2000044383A1 (en) * 1999-01-29 2000-08-03 Senju Pharmaceutical Co., Ltd. Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives
WO2001034554A1 (en) * 1999-11-09 2001-05-17 Alcon Universal Ltd. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Shohoyaku search drug prescription", LATANOPROSTEKI(XALATAN) NI TSUITE NO KENSAKU KEKKA, XP002970208, Retrieved from the Internet <URL:http://health.nikkei.co.jp/navi/ethical_drugs/data-a.cfm?yj_cd=1319739Q1029&pill_cd=129200&allRecCnt=1&pageno=1&seibun=&kigou=&seihin=xalatan&search_flg=true> [retrieved on 20030603] *
"Shohoyaku search drug prescription", TIMOLOL MALEATE-EKI(TIMOPTOL) NI TSUITE NO KENSAKU KEKKA, XP002970209, Retrieved from the Internet <URL:http://health.nikkei.co.jp/navi/ethical_drugs/data-a.cfm?yj_cd=1319702Q2022&pill_cd=065900&allRecCnt=4&pageno=1&seihein=&kigou=&seihin=Timoptol&search_flg=true> [retrieved on 20030603] *
KEIZO TAKAHASHI: "PRK(laser kussetsu kyosei kakumaku setsujojutsu)", JOURNAL OF THE EYE, vol. 16, no. 8, 1999, pages 1075 - 1080, XP002970207 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105998030A (en) * 2016-05-17 2016-10-12 温州医科大学 Application of prostaglandin F2a receptor stimulant in preparation of drug for inhibiting myopia and application method of prostaglandin F2a receptor stimulant
WO2022136192A1 (en) * 2020-12-23 2022-06-30 Essilor International Method of evaluating the efficiency of a myopia control solution

Also Published As

Publication number Publication date
AU2003236044A1 (en) 2003-10-27
JP2005289814A (en) 2005-10-20

Similar Documents

Publication Publication Date Title
AU2019200623B2 (en) Compositions and methods for the treatment of presbyopia
US6273092B1 (en) Methods for treating various eye disorders
TWI351959B (en) Combination of brimonidine and timolol for topical
KR102598047B1 (en) Methods and storage-stable compositions for the treatment of refractive errors in the eye
KR101689847B1 (en) Eye drop with difluprednate for macular edema treatment
BALLINTINE et al. Improvement of the coefficient of outflow in glaucomatous eyes: Prolonged local treatment with epinephrine
US9968594B2 (en) Compositions and methods for the treatment of presbyopia
Bartlett et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis
KR20210076941A (en) Compositions and methods for the treatment of presbyopia
WO2017160548A1 (en) Compositions and methods for the treatment of presbyopia
JP2022537139A (en) Carbachol-brimonidine preparations for potentiating anti-presbyopic effects
EP3231428B1 (en) Pharmacotherapy for preventing or treating glaucoma
Sandoval et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation
WO2003086465A1 (en) Drugs for myopia correction surgery
CN117979951A (en) Application of chondroitin sulfate for relieving ocular pain
AU2022276728A1 (en) Eye drop for suppressing myopia
WO2018074421A1 (en) Ophthalmic agent and ophthalmologic drug
JP2007070350A (en) Preparation for ocular-mucous membrane application
Halasa et al. Thymoxamine therapy for angle-closure glaucoma
WO2020138135A1 (en) Composition for ophthalmic use
Zarei et al. Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy
Gayre Medical management of thyroid eye disease
WO2019135927A1 (en) Contact lens compositions and methods for the treatment of presbyopia
KR20090056268A (en) Pharmaceutical composition for topical dosage
WO2016205071A1 (en) Compositions and methods for the treatment of presbyopia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP